Cohance Lifesciences Ltd

Cohance Lifesciences Capital Structure Change

Jasti group entities transferred 51,00,000 Cohance shares to Jasub Property Holdings LLP via inter-se block deals. Combined group holding remains 6.36%.

Cohance Lifesciences Business Update

Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.

Cohance Lifesciences Management Change

Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.

Cohance Lifesciences Earnings Call Transcript: Key Takeaways

Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.

Cohance Lifesciences Results Update

Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.

Cohance Lifesciences Investor Presentation: Key Takeaways

Q2FY27 revenue INR 4,766 Mn, down 14.2% YoY but up 12.9% QoQ. Adjusted EBITDA margin 9.6%, adjusted PAT INR 74 Mn back positive. Strategy centres on One Cohance integration and H2 recovery.

Cohance Lifesciences Q2 FY27 Results: Net Profit ₹2.3 Cr, Down 96.5% YoY

Cohance Lifesciences Ltd reported revenue from operations of ₹476.6 Cr (-14.2% YoY) and net profit of ₹2.3 Cr (-96.5% YoY) for Q2 FY27.

Key figure

Net profit ₹2.3 Cr · -96.5% YoY

Cohance Lifesciences Adverse Business Impact

Cohance Lifesciences disclosed a TGPCB closure order halting manufacturing at its Suryapet site after an industrial accident. The financial impact cannot yet be quantified.